Breast Cancer Management: Quality-of-Life and Cost Considerations
The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
The purpose of this article was to provide a literature-based extensive overview of the quality-of-life and cost issues posed by the management of breast cancer. Incidence and mortality rates vary widely in different countries. Breast cancer accounts approximately for one-fifth of all deaths in women aged 40-50 years. The 1994-1998 incidence rate in the US population was on average 114.3 per 100 000 women. Treatment options include surgery, radiotherapy and drug therapy (cytotoxic and endocrine drugs). All treatment options affect patients' health-related quality of life (HR-QOL) in various ways. The use of cytotoxic agents has a particularly large HR-QOL impact. HR-QOL questionnaires are complex tools, not routinely used in breast cancer trials.Worldwide, around 10 million individuals develop cancer each year; this figure is expected to increase to 15 million in 2020. For all cancers, the total economic burden of this disease worldwide was projected by the authors to be in the range of $US 300-400 billion in 2001 (about $US 100-140 billion as direct costs and the remainder as indirect costs [morbidity and mortality]). According to the National Institute of Health (NIH), the total cost of cancer was estimated at $US 156.7 billion in 2001 in US ($US 56.4 billion as direct costs, $US 15.6 as indirect morbidity costs, and $US 84.7 billion as indirect mortality costs). Based on limited information, in the US, breast cancer can be projected to account for about one-fifth/one-fourt…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, cancer related burden may persist even if the neoplasm has been treated successfully [4–8].”
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Veronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., Gallus, G., Greco, M., Luini, A., Marubini, E., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107023050102 · Cited by 1,599
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
McPherson, K. (2000) · BMJ · doi:10.1136/bmj.321.7261.624 · Cited by 1,570
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,423
Fisher, B., Redmond, C., Fisher, E. R., Bauer, M., Wolmark, N., Wickerham, D. L., Deutsch, M., Montague, E., Margolese, R., & Foster, R. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121102 · Cited by 1,376
A chronic disease score from automated pharmacy data
Von Korff, M., Wagner, E. H., & Saunders, K. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 961
Ten- to Fourteen-Year Effect of Screening on Breast Cancer Mortality 2
(1982) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/69.2.349 · Cited by 840
Research works printed but not linked: 12
- 16, eb, 1325, 1
- Fisher, 1989, N Engl J Med, 320, 478
- Radice, 2000, Qual Life Res, 9, 1065
- Selby, 1984, Rev Endocr Related Cancer, 14, 245
- Mor, 1994, J Natl Cancer Inst Monogr, 16, 191
- Edlund, 1989, Oncol Nurs Forum, 16, 691
- Schagen, 2000, O-N-E, 1, 48
- Brown, 1994, NCI, 13, 255
- Thom, 1996, In Vivo, 10, 255
- Brown, 1990, NCI, 5, 69
- Shapiro, 1982, J Natl Cancer Inst, 326, 653
- McPherson, 1994, BMJ, 309, 1003, 10.1136/bmj.309.6960.1003 · DOI
Cited by
Use of Statistics to Assess the Global Burden of Breast Cancer
Parkin, D. M., & Fernandez, L. M. G. (2006) · The Breast Journal · doi:10.1111/j.1075-122x.2006.00205.x · Cited by 497
Anderson, B. O., Shyyan, R., Eniu, A., Smith, R. A., Yip, C.-H., Bese, N. S., Chow, L. W. C., Masood, S., Ramsey, S. D., & Carlson, R. W. (2006) · The Breast Journal · doi:10.1111/j.1075-122x.2006.00199.x · Cited by 359
Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service.
Blumen, H., Fitch, K., & Polkus, V. (2016) · Europe PMC (PubMed Central) · Cited by 256
Coping with breast cancer in newly diagnosed Iranian women
Taleghani, F., Yekta, Z. P., & Nasrabadi, A. N. (2006) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2006.03808_1.x · Cited by 240
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O’Byrne, K. J. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 211
Metadata
- Authors
- Radice, D., & Redaelli, A.
- Corresponding author
- Redaelli, Alberto
- Venue
- PharmacoEconomics
- Published
- 2003
- Volume
- 21
- Issue
- 6
- Pages
- 383-396
- ISSN
- 1170-7690 (ISSN-L)
- OpenAlex
- W2092610057
- Cited by
- 146
- References
- 53
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 2 · 2020: 8 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 4 · 2015: 6 · 2014: 2 · 2013: 9 · 2012: 6
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PharmacoEconomics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- breast cancer, health-related quality of life, cancer treatment costs, economic burden of cancer, cytotoxic chemotherapy, endocrine therapy, radiotherapy, breast cancer incidence and mortality, cost-effectiveness, cancer screening, developing countries
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Breast Neoplasms, Female, Humans, Middle Aged, Quality of Life, Surveys and Questionnaires, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breast Cancer Management: Quality-of-Life and Cost Considerations. https://app.cochat.ai/papers/10.2165/00019053-200321060-00003
- The paper
- Radice, D., & Redaelli, A. (2003). Breast Cancer Management: Quality-of-Life and Cost Considerations. PharmacoEconomics. https://doi.org/10.2165/00019053-200321060-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.